Wire · opportunities
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
Outlook Therapeutics CEO Bob Jahr highlights the FDA approval of LYTENAVA, the first FDA-approved ophthalmic bevacizumab formulation for wet AMD in the U.S., and discusses plans for its commercial launch aiming at capturing a significant share of the retina market with potential $500 million annual sales by 2030.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 10 Sep 2026 and 11 Sep 2026.
◆ ◆ The Wire takeaway
Bevacizumab ophthalmic treatment now has FDA backing, opening the U.S. retina market to new approved therapies. You must prepare to navigate shifting physician demand and reimbursement to capitalise on this launch.
◆ Coverage
3 sources · first reported 10 Sep 2026 · latest 11 Sep 2026
◆ Related on Wire
◆ Topics